廣告
香港股市 已收市
  • 恒指

    17,941.78
    -170.85 (-0.94%)
     
  • 國指

    6,374.66
    -47.15 (-0.73%)
     
  • 上證綜指

    3,032.63
    +3.71 (+0.12%)
     
  • 滬深300

    3,541.53
    +15.40 (+0.44%)
     
  • 美元

    7.8106
    +0.0007 (+0.01%)
     
  • 人民幣

    0.9284
    +0.0004 (+0.04%)
     
  • 道指

    38,589.16
    -57.94 (-0.15%)
     
  • 標普 500

    5,431.60
    -2.14 (-0.04%)
     
  • 納指

    17,688.88
    +21.32 (+0.12%)
     
  • 日圓

    0.0494
    -0.0001 (-0.22%)
     
  • 歐元

    8.3555
    -0.0313 (-0.37%)
     
  • 英鎊

    9.9060
    -0.0600 (-0.60%)
     
  • 紐約期油

    78.49
    -0.13 (-0.17%)
     
  • 金價

    2,348.40
    +30.40 (+1.31%)
     
  • Bitcoin

    66,171.88
    +861.48 (+1.32%)
     
  • CMC Crypto 200

    1,405.79
    -12.08 (-0.85%)
     

Roche To Ride Booming Obesity Treatment Market With Newly-Acquired Drug Candidate

Roche To Ride Booming Obesity Treatment Market With Newly-Acquired Drug Candidate
Roche To Ride Booming Obesity Treatment Market With Newly-Acquired Drug Candidate

Thursday, Genentech, a unit of Roche Holdings AG (OTC:RHHBY), released results from the Phase 1b trial of CT-388, a dual GLP-1/GIP receptor agonist being developed for the treatment of obesity and type 2 diabetes.

The study found that a once-weekly subcutaneous injection of CT-388 over 24 weeks resulted in significant weight loss in healthy adults with obesity compared to placebo.

The weight loss achieved with CT-388 was clinically meaningful, with a mean placebo-adjusted weight loss of 18.8% (p-value < 0.001).

At week 24, 100% of CT-388 treated participants achieved a weight loss of over 5%, 85% achieved over 10%, 70% achieved over 15%, and 45% achieved over 20%.

廣告

The treatment was well tolerated, with mild to moderate gastrointestinal-related adverse events being the most common, consistent with the incretin class of medicines that CT-388 belongs to.

All participants with a pre-diabetes status at baseline became normoglycemic after 24 weeks of CT-388 treatment, whereas the glycemic status of participants treated with placebo remained largely unchanged during this period.

CT-388 belongs to the class of incretin-based medicines that aim to regulate blood sugar and reduce appetite.

It selectively targets and activates two specific receptors in the body, GLP-1 and GIP, which integrate nutrient-derived signals to control food intake, energy absorption and assimilation.

An additional cohort from the ongoing placebo-controlled Phase 1b trial of CT-388 will evaluate obese patients (BMI>30 kg/m2) with type 2 diabetes over a 12-week treatment duration.

Roche expects data from this additional cohort in the second half of 2024.

In December, Roche agreed to acquire a privately held obesity company, Carmot Therapeutics, for $2.7 billion in cash. Additionally, Carmot’s equity holders are entitled to receive payments of up to $400 million depending on achieving certain milestones.

Once-a-week injection CT-388 is Carmot’s obesity candidate.

Photo by Vidmir Rais via Pixabay

"ACTIVE INVESTORS' SECRET WEAPON" Supercharge Your Stock Market Game with the #1 "news & everything else" trading tool: Benzinga Pro - Click here to start Your 14-Day Trial Now!

Get the latest stock analysis from Benzinga?

This article Roche To Ride Booming Obesity Treatment Market With Newly-Acquired Drug Candidate originally appeared on Benzinga.com

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.